DPP4 and type 2 diabetes mellitus: Regarding hypoglycemic treatment of T2DM patients, the most common drugs were dipeptidyl peptidase-4 inhibitors (DPP-4i) in four patients (50%), followed by meglitinides in three patients (37.5%), glucagon-like peptide-1 receptor agonists (GLP-1ra) (37.5%) in three patients, and insulin in two patients (25%).